What is Skye Bioscience, Inc.'s earnings per share (EPS)?

Skye Bioscience, Inc. (SKYE) reported diluted earnings per share of -$1.41 for fiscal year 2025. This represents a -93.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Skye Bioscience, Inc. (SKYE) Financials

SKYE

FY2025 annual

Net Income -$55.9M -110.5% YoY

EPS (Diluted) -$1.41 -93.2% YoY

Free Cash Flow -$43.1M -60.5% YoY

Operating Cash Flow -$43.1M -70.6% YoY

Market Cap $9.0M as of Sep 12, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SKYE SEC filings page.

This page shows Skye Bioscience, Inc. (SKYE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SKYE FY2025 2026-08-30

Development spending, not commercial revenue, is the dominant mechanic, with financing supplying the balance sheet while operating cash flow remains negative.

The $83.6M financing inflow in FY2024 coincided with assets of $72.8M, showing the balance sheet was replenished externally rather than by operations. By FY2025, financing was only $29.6K against operating cash flow of -$43.1M, so the business was consuming capital while its funding contribution largely disappeared.

With no reported revenue, FY2025 R&D reached $42.4M versus SG&A of $15.8M, a cost structure centered on development rather than a scaled commercial engine. Operating loss widened from $30.2M in FY2024 to $58.2M in FY2025 as R&D expanded, linking the deterioration primarily to heavier development investment.

The balance sheet remained equity-positive at $20.0M against liabilities of $8.3M, so FY2025 was structurally different from the negative-equity periods. A current ratio of 3.3x coexisted with a liquidity reading of 7.2 months, a cushion measured against the latest annual operating outflow rather than evidence of operating self-sufficiency.

Financial Health Signals

Financial health score not available

Skye Bioscience, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

Skye Bioscience, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Skye Bioscience, Inc. reported a net loss of $55.9M while operations used $43.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$10.9M

YoY+39.6%

QoQ+12.8%

Skye Bioscience, Inc.'s EBITDA was -$10.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 39.6% from the same quarter a year earlier. Against the prior quarter it is up 12.8%.

Net Income

-$10.8M

YoY+38.8%

QoQ+13.8%

Skye Bioscience, Inc. reported -$10.8M in net income in Q2 2026. This represents an increase of 38.8% from the same quarter a year earlier. Against the prior quarter it is up 13.8%.

EPS (Diluted)

-$0.27

YoY+38.6%

QoQ+15.6%

Skye Bioscience, Inc. earned -$0.27 per diluted share (EPS) in Q2 2026. This represents an increase of 38.6% from the same quarter a year earlier. Against the prior quarter it is up 15.6%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$7.1M

YoY+33.7%

QoQ+16.8%

Skye Bioscience, Inc. recorded an outflow of $7.1M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 33.7% from the same quarter a year earlier. Against the prior quarter it is up 16.8%.

Cash & Debt

$8.1M

YoY-66.2%

QoQ-1.0%

5Y CAGR+9.2%

10Y CAGR+25.5%

Skye Bioscience, Inc. held $8.1M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

35M

YoY+14.3%

QoQ+0.8%

5Y CAGR-38.9%

10Y CAGR+5.9%

Skye Bioscience, Inc. had 35M shares outstanding in Q2 2026. This represents an increase of 14.3% from the same quarter a year earlier. Against the prior quarter it is up 0.8%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

None of these metrics is reported for Q2 2026.

Capital Allocation

R&D Spending

$3.9M

YoY-72.5%

QoQ-50.3%

Skye Bioscience, Inc. invested $3.9M in research and development in Q2 2026. This represents a decrease of 72.5% from the same quarter a year earlier. Against the prior quarter it is down 50.3%.

Capital Expenditures

Skye Bioscience, Inc. reported no capital expenditure in Q2 2026.

Share Buybacks

Not reported for Q2 2026.

SKYE Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SKYE quarterly income statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
R&D Expenses	N/A	$42.4M+126.5%	$18.7M+221.4%	$5.8M-3.2%	$6.0M+105.1%	$2.9M+50.8%	$1.9M-13.1%	$2.2M+578.2%	$330K+6.0%	$311K-66.8%	$939K+63.0%	$576K+153.2%	$228K	N/A	N/A
SG&A Expenses	N/A	$15.8M-10.9%	$17.7M+125.7%	$7.9M+28.8%	$6.1M+24.0%	$4.9M+13.2%	$4.3M-1.1%	$4.4M+0.7%	$4.4M	N/A	N/A	$3.7M	N/A	$120K+4657.1%	$3K
Operating Income	N/A	-$58.2M-92.6%	-$30.2M+13.1%	-$34.7M-89.7%	-$18.3M-133.3%	-$7.8M-24.8%	-$6.3M+5.2%	-$6.6M-41.3%	-$4.7M	N/A	N/A	-$4.3M	N/A	-$120K-3024.5%	$4K
EBITDA	N/A	-$57.4M-92.1%	-$29.9M+13.6%	-$34.6M-90.2%	-$18.2M-132.9%	-$7.8M-24.3%	-$6.3M+5.2%	-$6.6M-41.4%	-$4.7M	N/A	N/A	-$4.3M	N/A	-$110K	N/A
Interest Expense	N/A	$0-100.0%	$749K-17.3%	$906K+36.3%	$665K-13.5%	$769K+8.9%	$706K-29.4%	$1.0M+956.0%	$95K+14107.3%	$667	N/A	N/A	N/A	$2K	N/A
Income Tax	N/A	$5K-46.4%	$10K+179.8%	$4K-46.6%	$7K+221.0%	$2K+31.3%	$2K0.0%	$2K-2.6%	$2K+2.6%	$2K0.0%	$2K-6.8%	$2K-31.5%	$3K	N/A	$246
Net Income	N/A	-$55.9M-110.5%	-$26.6M+29.4%	-$37.6M-93.2%	-$19.5M-128.6%	-$8.5M-29.9%	-$6.6M-723.7%	$1.1M	N/A	N/A	N/A	-$4.8M	N/A	-$120K-2770.3%	$5K
EPS (Basic)	N/A	-$1.41-93.2%	-$0.73+86.4%	-$5.37+38.8%	-$8.77-43750.0%	-$0.02+33.3%	-$0.03-400.0%	$0.01+106.3%	-$0.16-45.5%	-$0.11+35.3%	-$0.17	N/A	N/A	N/A	N/A
EPS (Diluted)	-$1.27	-$1.41-93.2%	-$0.73	-$5.37	-$8.77	-$0.02	-$0.03	-$0.05+68.8%	-$0.16-45.5%	-$0.11	-$0.17	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	40M+8.7%	36M	7M	2M	407M	231M	170M+40.0%	121M+334.2%	28M	19M	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$3.9M-72.5%	$7.9M+10.3%	N/A	$9.4M+91.6%	$14.3M+251.5%	$7.2M+269.8%	N/A	$4.9M+289.2%
SG&A Expenses	$3.9M-0.9%	$4.7M+3.9%	N/A	$3.9M-15.8%	$3.9M-9.7%	$4.6M+8.5%	N/A	$4.6M+107.5%
Operating Income	-$11.1M+39.4%	-$12.7M-7.8%	N/A	-$13.3M-167.0%	-$18.2M-117.0%	-$11.8M-91.1%	N/A	-$5.0M+79.9%
EBITDA	-$10.9M+39.6%	-$12.5M-7.9%	N/A	-$13.1M-165.9%	-$18.1M-115.6%	-$11.6M-89.1%	N/A	-$4.9M+80.1%
Interest Expense	$3K	$2K+51.4%	N/A	$0+100.0%	$0-100.0%	$1K-99.7%	N/A	-$91K-133.5%
Income Tax	$3K0.0%	$0-100.0%	N/A	$0	$3K-57.9%	$2K0.0%	N/A	$0
Net Income	-$10.8M+38.8%	-$12.5M-12.7%	N/A	-$12.8M-227.2%	-$17.6M-123.0%	-$11.1M-121.2%	N/A	-$3.9M+84.4%
EPS (Basic)	-$0.27+38.6%	-$0.32-14.3%	-$0.36-44.0%	-$0.32-220.0%	-$0.44-120.0%	-$0.28-55.6%	-$0.25-124.8%	-$0.10+96.8%
EPS (Diluted)	-$0.27+38.6%	-$0.32-14.3%	-$0.36-44.0%	-$0.32-220.0%	-$0.44-120.0%	-$0.28-55.6%	-$0.25-124.8%	-$0.10
Diluted Shares (Avg)	40M+0.1%	40M+0.1%	N/A	40M+2.2%	40M+2.6%	40M+41.6%	N/A	39M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.

SKYE Balance Sheet

SKYE quarterly balance sheet

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$28.3M-61.1%	$72.8M+509.4%	$11.9M+31.1%	$9.1M-7.5%	$9.9M+268.9%	$2.7M+33.8%	$2.0M+2.0%	$2.0M+251.2%	$557K+72.3%	$323K-90.8%	$3.5M+907.9%	$348K+147.3%	$141K+228.4%	$43K
Current Assets	$27.1M-61.7%	$70.8M+507.9%	$11.7M+30.3%	$8.9M-7.0%	$9.6M+260.8%	$2.7M+33.6%	$2.0M+2.1%	$2.0M+251.5%	$556K+98.9%	$279K-91.9%	$3.5M+1019.9%	$308K+197.5%	$104K+170.3%	$38K
Cash & Equivalents	$5.9M-91.4%	$68.4M+5345.1%	$1.3M+1.0%	$1.2M-86.1%	$9.0M+263.8%	$2.5M+34.9%	$1.8M-1.3%	$1.9M+613.0%	$260K+301.0%	$65K-98.0%	$3.2M+1453.7%	$207K+346.1%	$46K+76.0%	$26K
Short-Term Investments	$19.9M	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$35K+403.9%	$7K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$8.3M+79.7%	$4.6M-67.2%	$14.1M+16.1%	$12.1M+203.7%	$4.0M+79.7%	$2.2M+53.3%	$1.4M-91.7%	$17.5M+324.5%	$4.1M+27.5%	$3.2M-26.5%	$4.4M+449.1%	$802K+148.3%	$323K+7368.0%	$4K
Current Liabilities	$8.2M+89.1%	$4.3M-68.8%	$13.9M+14.7%	$12.1M+209.8%	$3.9M+397.0%	$787K-18.9%	$971K-93.9%	$15.9M+1877.6%	$806K+21.8%	$662K+13.8%	$582K-27.4%	$801K+339.8%	$182K+4111.6%	$4K
Non-Current Liabilities	$84K-69.2%	$273K+59.5%	$171K	$0-100.0%	$79K-94.5%	$1.4M+200.0%	$478K-69.8%	$1.6M+186.7%	$551K-50.4%	$1.1M-54.8%	$2.5M+305265.5%	$805-99.4%	$141K	$0
Total Equity	$20.0M-70.6%	$68.2M+3296.9%	-$2.1M+29.1%	-$3.0M-151.3%	$5.9M+1200.9%	$451K-17.7%	$548K+103.5%	-$15.6M-336.0%	-$3.6M-22.5%	-$2.9M-226.6%	-$892K-96.7%	-$454K-149.0%	-$182K-572.4%	$39K
Retained Earnings	-$186.9M-42.7%	-$130.9M-25.5%	-$104.4M-56.4%	-$66.7M-41.2%	-$47.3M-22.0%	-$38.7M-20.4%	-$32.2M+3.2%	-$33.2M-136.8%	-$14.0M-28.3%	-$10.9M-41.0%	-$7.8M-165.9%	-$2.9M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$11.0M-78.8%	$19.4M-70.0%	$28.3M-61.1%	$41.3M-49.3%	$52.2M-40.2%	$64.8M-31.7%	$72.8M+509.4%	$81.5M+422.5%
Current Assets	$11.0M-78.3%	$18.6M-70.5%	$27.1M-61.7%	$39.9M-50.0%	$50.6M-41.9%	$63.0M-33.4%	$70.8M+507.9%	$79.8M+422.1%
Cash & Equivalents	$8.1M-66.2%	$8.1M-82.4%	$5.9M-91.4%	$18.4M-72.6%	$23.8M-67.8%	$46.4M-44.3%	$68.4M+5345.1%	$67.4M+1215.0%
Short-Term Investments	$2.0M-91.9%	$9.0M-30.0%	$19.9M	$16.9M	$24.7M	$12.8M	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$11.5M+35.9%	$10.4M+87.7%	$8.3M+79.7%	$8.5M+48.1%	$8.5M-41.3%	$5.5M-65.3%	$4.6M-67.2%	$5.7M-58.8%
Current Liabilities	$11.5M+38.7%	$10.4M+95.6%	$8.2M+89.1%	$8.4M+48.8%	$8.3M-42.0%	$5.3M-66.3%	$4.3M-68.8%	$5.6M-59.0%
Non-Current Liabilities	$0-100.0%	$0-100.0%	$84K-69.2%	$120K+11.2%	$172K+32.8%	$223K+48.0%	$273K+59.5%	$108K-43.3%
Total Equity	-$497K-101.1%	$9.0M-84.8%	$20.0M-70.6%	$32.8M-56.7%	$43.7M-40.0%	$59.3M-24.9%	$68.2M+3296.9%	$75.8M+4371.5%
Retained Earnings	-$210.2M-31.6%	-$199.4M-40.4%	-$186.9M-42.7%	-$172.4M-42.3%	-$159.7M-36.1%	-$142.1M-29.8%	-$130.9M-25.5%	-$121.2M-21.2%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

SKYE Cash Flow Statement

SKYE quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	-$38.8M	-$43.1M-70.6%	-$25.2M-80.9%	-$14.0M-9.5%	-$12.7M-96.8%	-$6.5M-6.9%	-$6.1M-0.4%	-$6.0M-52.9%	-$3.9M	N/A	N/A	-$3.7M	N/A	-$14K-851.8%	$2K
Depreciation & Amortization	N/A	$723K+142.2%	$299K+140.4%	$124K+8.0%	$115K+236.9%	$34K+1723.2%	$2K+28.0%	$1K-5.3%	$2K-80.8%	$8K-46.1%	$15K+49.9%	$10K+421.6%	$2K-82.5%	$11K	N/A
Stock-Based Compensation	N/A	$7.8M-6.6%	$8.3M+742.3%	$988K+57.0%	$629K-27.6%	$869K+187.1%	$303K-55.5%	$680K+0.8%	$675K+10.9%	$609K-13.8%	$706K+70.5%	$414K+3746.8%	$11K	N/A	N/A
Capital Expenditures	$0	$6K-99.6%	$1.6M+12681.1%	$13K-55.3%	$28K-69.1%	$91K+1156.8%	$7K	N/A	$4K-77.7%	$20K+76.8%	$11K+460.9%	$2K-91.5%	$23K-52.6%	$49K	N/A
Free Cash Flow	-$38.8M	-$43.1M-60.5%	-$26.8M-92.2%	-$14.0M-9.3%	-$12.8M-94.5%	-$6.6M-8.3%	-$6.1M	N/A	-$3.9M	N/A	N/A	-$3.7M	N/A	-$64K	N/A
Investing Cash Flow	$23.2M	-$19.5M-7839.4%	-$246K-103.7%	$6.6M+26.5%	$5.2M+5838.6%	-$91K-1156.8%	-$7K	N/A	-$4K+77.7%	-$20K	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	-$161K	$30K-100.0%	$83.6M+408.2%	$16.4M+7975.4%	-$209K-101.6%	$13.1M+95.2%	$6.7M+11.6%	$6.0M+8.4%	$5.5M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$7.1M+33.7%	-$8.6M+6.8%	-$9.8M-19.5%	-$13.4M-153.9%	-$10.7M-51.5%	-$9.2M-95.1%	-$8.2M-112.6%	-$5.3M-29.8%
Depreciation & Amortization	$158K-15.8%	$173K-2.5%	$180K+2.7%	$179K+276.5%	$187K+527.9%	$177K+543.6%	$175K+103.5%	$48K+271.6%
Stock-Based Compensation	$1.3M-37.5%	$1.5M-32.0%	N/A	$1.9M-0.4%	$2.0M+11.2%	$2.2M-11.1%	N/A	$1.9M+1099.5%
Capital Expenditures	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$6K+98.4%	$50K+612.9%	$1.5M+41238.4%
Free Cash Flow	-$7.1M+33.7%	-$8.6M+6.9%	-$9.8M-18.8%	-$13.4M-97.1%	-$10.7M-50.8%	-$9.2M-95.1%	-$8.2M-113.5%	-$6.8M-67.1%
Investing Cash Flow	$7.1M+160.2%	$10.9M+185.1%	-$2.8M-3200.9%	$8.0M+651.2%	-$11.9M-36418.6%	-$12.8M-1221.7%	$90K+1388.4%	-$1.4M-234.7%
Financing Cash Flow	-$101K-656.3%	-$72K	$11K+103.2%	$0	$18K+100.9%	$0-100.0%	$6K+124.8%	$0-100.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

SKYE Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SKYE quarterly financial ratios

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Return on Equity	-279.3%-240.3pp	-39.0%	N/A	N/A	-145.3%+1310.1pp	-1455.4%-1647.3pp	191.9%	N/A	N/A	N/A	N/A	N/A	N/A	11.7%
Return on Assets	-197.5%-161.0pp	-36.5%+278.8pp	-315.3%-101.4pp	-213.8%-127.3pp	-86.5%+159.1pp	-245.6%-298.2pp	52.7%	N/A	N/A	N/A	-137.9%	N/A	-85.5%-96.0pp	10.5%
Current Ratio	3.30-13.0x	16.32+15.5x	0.84+0.1x	0.74-1.7x	2.46-0.9x	3.38+1.3x	2.05+1.9x	0.12-0.6x	0.69+0.3x	0.42-5.5x	5.94+5.6x	0.39-0.2x	0.57-8.3x	8.87
Debt-to-Equity	0.41+0.3x	0.07	N/A	N/A	0.68-4.2x	4.93+2.3x	2.64	N/A	N/A	N/A	N/A	N/A	N/A	0.11

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	N/A	-138.8%-120.1pp	N/A	-38.8%-33.7pp	-40.4%-29.5pp	-18.7%-12.4pp	N/A	-5.1%+1466.4pp
Return on Assets	-97.8%-64.0pp	-64.4%-47.3pp	N/A	-30.9%-26.1pp	-33.8%-24.7pp	-17.1%-11.8pp	N/A	-4.8%+155.1pp
Current Ratio	0.95-5.1x	1.78-10.1x	3.30-13.0x	4.77-9.4x	6.090.0x	11.85+5.9x	16.32+15.5x	14.19+13.1x
Debt-to-Equity	N/A	1.15+1.1x	0.41+0.3x	0.26+0.2x	0.190.0x	0.09-0.1x	0.07	0.08-8.1x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Skye Bioscience, Inc. SKYE	FY2025	N/A	-$55.9M	N/A	$9.0M	—
Avalo Therapeutics, Inc. AVTX	FY2025	$59K	-$78.3M	N/A	$864.5M	—
Cardiff Oncology, Inc. CRDF	FY2025	$593K	-$46K	-7.7%	$94.1M	—
Zura Bio Limited ZURA	FY2025	N/A	-$68.7M	N/A	$499.3M	—
Forte Biosciences, Inc. FBRX	FY2025	N/A	-$69.4M	N/A	$1.6B	—
TuHURA Biosciences, Inc. HURA	FY2025	$0	-$31.0M	N/A	$130.6M	—

Where Skye Bioscience, Inc. Ranks

Frequently Asked Questions

Is Skye Bioscience, Inc. profitable?

No, Skye Bioscience, Inc. (SKYE) reported a net income of -$55.9M in fiscal year 2025.

What is Skye Bioscience, Inc.'s EBITDA?

Skye Bioscience, Inc. (SKYE) had EBITDA of -$57.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Skye Bioscience, Inc.'s return on equity (ROE)?

Skye Bioscience, Inc. (SKYE) has a return on equity of -279.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Skye Bioscience, Inc.'s free cash flow?

Skye Bioscience, Inc. (SKYE) recorded an outflow of $43.1M in free cash flow during fiscal year 2025. This represents a -60.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Skye Bioscience, Inc.'s operating cash flow?

Skye Bioscience, Inc. (SKYE) recorded an outflow of $43.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Skye Bioscience, Inc.'s total assets?

Skye Bioscience, Inc. (SKYE) had $28.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Skye Bioscience, Inc.'s capital expenditures?

Skye Bioscience, Inc. (SKYE) invested $6K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Skye Bioscience, Inc. spend on research and development?

Skye Bioscience, Inc. (SKYE) invested $42.4M in research and development during fiscal year 2025.

How many shares does Skye Bioscience, Inc. have outstanding?

Skye Bioscience, Inc. (SKYE) had 33M shares outstanding as of fiscal year 2025.

What is Skye Bioscience, Inc.'s current ratio?

Skye Bioscience, Inc. (SKYE) had a current ratio of 3.30 as of fiscal year 2025, which is generally considered healthy.

What is Skye Bioscience, Inc.'s debt-to-equity ratio?

Skye Bioscience, Inc. (SKYE) had a debt-to-equity ratio of 0.41 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Skye Bioscience, Inc.'s return on assets (ROA)?

Skye Bioscience, Inc. (SKYE) had a return on assets of -197.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Skye Bioscience, Inc.'s P/E ratio?

Skye Bioscience, Inc. (SKYE) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $9.0M as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Skye Bioscience, Inc.'s price-to-sales ratio?

Skye Bioscience, Inc. (SKYE) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $9.0M as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Skye Bioscience, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Skye Bioscience, Inc. (SKYE) held $25.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $43.1M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Skye Bioscience, Inc.'s Piotroski F-Score?

Skye Bioscience, Inc. (SKYE) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Skye Bioscience, Inc.'s earnings high quality?

Skye Bioscience, Inc. (SKYE) reported a net loss of $55.9M while operations used $43.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.